drugset / Trial / NCT05808166

Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women

NCT05808166

RandomizedParallel-groupTriple-blindPrevention

Summary

This is a phase II randomized, observer-blinded, placebo-controlled study with 3 arms enrolling a total of 2,358 participants. The arms are composed of Arm 1, pregnant participants receiving Hecolin® (N=1,104) with immunogenicity subset (n=150), Arm 2, pregnant participants receiving placebo (N=1,104) with immunogenicity subset (n=150), and Arm 3, non-pregnant participants receiving Hecolin® (N=150) of which all participants in this arm will be included in the immunogenicity subset.

Timeline

Start
2024-05-02
Primary completion
2025-11
Completion
2026-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Hecolin® Vaccine